Major histocompatibility complex class I presenting ovalbumin-derived peptide (MHC I-OVA)

Classical MHC class I molecules presenting ovalbumin (OVA) peptides, specifically the SIINFEKL epitope, represent a fundamental model system in cellular immunology (Porgador et al., 1997). This complex consists of a polymorphic MHC class I heavy chain (such as H-2Kb in mice), beta-2 microglobulin, and the 8-amino acid peptide SIINFEKL derived from chicken egg ovalbumin. Its primary biological function is to serve as a ligand for specific T-cell receptors (TCRs), most notably the OT-I TCR, to initiate CD8+ T-cell activation and cytotoxic responses (Hogquist et al., 1994). In the pharmaceutical and biotech industry, this system is not a direct therapeutic target for human disease but is an essential tool for the preclinical development and validation of immunotherapies, including vaccines, TCR-like antibodies, and adoptive cell therapies. By using OVA as a surrogate tumor or viral antigen, researchers can precisely quantify antigen presentation and T-cell effector function in vivo. The system has been instrumental in elucidating the mechanisms of cross-presentation and the requirements for robust anti-tumor immunity (Rock et al., 1990). Consequently, it remains one of the most well-characterized and widely used benchmarks for evaluating the potency of novel immune-modulating drugs.

Other names

H-2Kb-SIINFEKL complexMHC-I/SIINFEKLOvalbumin-peptide/MHC complexpMHC complex

The complex is recognized by specific T-cell receptors (TCRs) on CD8+ T cells, triggering signal transduction that leads to T-cell proliferation, cytokine release, and targeted lysis of the presenting cell (Hogquist et al., 1994).